1. All Products
  2. TDF 300mg / 3TC 300mg / DTG 50mg, tab., for PEP
Public Pricelist

TDF 300mg / 3TC 300mg / DTG 50mg, tab., for PEP

https://medicalguidelines.msf.org/en/node/646
https://unicat.msf.org/cat/product/80458
STD DORATELD1TPEP

Valid Article

6.4.2.5 - Fixed-dose combinations of antiretroviral medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR27
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

TENOFOVIR (TDF) / LAMIVUDINE (3TC) / DOLUTEGRAVIR (DTG)

Therapeutic Action

Fixed-dose combination (FDC) of three antiretrovirals:

Indications

HIV infection, according to strengths recommended by WHO

Post Exposure Prophylaxis (PEP) after accidental exposure to blood or body fluids

Instructions for use

Two different codes depending on the packaging and the indication:

  • DORATELD1T-: 90-tablets packaging preferred for HIV treatment.
  • DORATELD1TPEP: 30-tablets packaging reserved for PEP (Post Exposure Prophylaxis).

In children, use DTG 10mg disp. (≥ 4 weeks and ≥ 3 kg) or 50mg (≥ 20 to < 25 kg) in combination with the fixed-dose combination ABC 120mg / 3TC 60mg.

Storage

Below 25ºC